Gene or Genome – Page 22

ITM Secures €188 Million to Enhance Radiopharmaceutical Pipeline and Strengthen Medical Radioisotope Manufacturing

1 year ago talkbio0Tagged actinium-225, Authority, BlackRock, cancer pipeline, Gastro-enteropancreatic neuroendocrine tumor, Investments, Isotopes, medical radioisotopes, Munich, Qatar, Radiopharmaceuticals, SLC22A18 gene, Technology, Temasek

ITM Isotope Technologies Munich, radiopharmaceutical biotech, Temasek, BlackRock, Qatar Investment Authority, medical radioisotopes, Lutetium-177, Actinium-225, cancer pipeline, gastroenteropancreatic neuroendocrine tumors (GEP-NETs)

Bristol Myers’ KRAS Confirmatory Data Avoid Amgen’s Flaws but Leave FDA Prospect Unclear

1 year ago talkbio0Tagged Accelerated, amgen, approval pathway, clinical benefits, confirmatory data, confirmatory trials, K-ras Oncogene, Myers, oncology therapies, squibb, United States Food and Drug Administration

Bristol Myers Squibb, KRAS confirmatory data, Amgen, FDA, accelerated approval pathway, oncology therapies, clinical benefits, confirmatory trials

Akeso and Summit’s Keytruda-Topping Results in NSCLC Generate Significant Interest at ASCO

1 year ago talkbio0Tagged Akeso, ASCO, Ivonescimab, Keytruda, Malignant Neoplasms, Non-Small Cell Lung Carcinoma, PDCD1 gene, summit, Vascular Endothelial Growth Factor A

Akeso, Summit, Keytruda, NSCLC, ASCO, Merck, Ivonescimab, PD-1, VEGF, Cancer Treatment

Lilly Strengthens Neuro Pipeline with $45M Deal for QurAlis’ Preclinical ALS and Dementia Treatment

1 year ago talkbio0Tagged ALS, Amyotrophic Lateral Sclerosis, Eli Lilly, neuro pipeline, Neurodegenerative Disorders, Oligonucleotides, preclinical treatment, Presenile dementia, QRL-204, QurAlis, splice-switching antisense, UNC13A gene

Lilly, QurAlis, ALS, dementia, neurodegenerative diseases, UNC13A, splice-switching antisense oligonucleotide, QRL-204, neuro pipeline, preclinical treatment

BMS Details Confirmatory Trial Win for KRAS Inhibitor Krazati

1 year ago talkbio0Tagged Accelerated, Approved, Confirmatory Trial, Inhibitor, K-ras Oncogene, KRAZATI, Myers, Non-Small Cell Lung Carcinoma, Pharmacotherapy, Progression-Free Survival, squibb, United States Food and Drug Administration

Bristol Myers Squibb, Krazati, KRAS inhibitor, confirmatory trial, non-small cell lung cancer (NSCLC), progression-free survival (PFS), chemotherapy, accelerated approval, FDA

CSL Seqirus Secures Fourth US Award to Enhance Bird Flu Vaccine Stockpile

1 year ago talkbio0Tagged Aves, BARDA, bird flu vaccine, CSHL1 gene, Government, Influenza in Birds, pandemic preparedness, public health protection, Seqirus, U.S., Vaccines

CSL Seqirus, bird flu vaccine, US government award, BARDA, pandemic preparedness, avian influenza, H5N1, vaccine stockpile, public health protection

Immunovant Shifts Focus to Next-Generation FcRn Inhibitor IMVT-1402, Delaying Batoclimab Development ###

1 year ago talkbio0Tagged Autoimmune Diseases, Batoclimab, Biological Factors, FCGRT gene, FcRn, Immunovant, IMVT-1402, Inhibitor, Roivant

Immunovant, IMVT-1402, FcRn inhibitor, Batoclimab, Autoimmune diseases, Vyvgart, Roivant, Biopharmaceuticals

Biotech Roundup: Compugen, Nxera Milestone Payments; Insmed Seeks $650M Offering

1 year ago talkbio0Tagged AstraZeneca, Bio, BMS, Breyanzi, Burning Mouth Syndrome, Celcuity, Compugen, K-ras Oncogene, luteolin-7-O-diglucuronide 4'-O-glucuronosyltransferase activity, milestone payments, Nordisk, Novartis, Nxera, United States Food and Drug Administration

Compugen, Nxera, milestone payments, Insmed, $650M offering, biotech, pharmaceuticals, Celcuity, Weave Bio, AstraZeneca, Novo Nordisk Foundation, FDA, LDT rule, BMS, Breyanzi, KRAS drug, Novartis

AstraZeneca and Daiichi Sankyo’s TROP2 ADC Demonstrates Clinically Meaningful Survival Improvement in Phase 3 Lung Cancer Subgroup

1 year ago talkbio0Tagged AstraZeneca, Continuance of life, Daiichi, Datopotamab, Deruxtecan, Improvement, Malignant neoplasm of lung, Nonsquamous Non-Small Cell Lung Cancer, Phase 3 trial, Sankyo, TACSTD2 gene, therapeutic autologous dendritic cells

AstraZeneca, Daiichi Sankyo, TROP2 ADC, Datopotamab Deruxtecan, Lung Cancer, Phase 3 Trial, Survival Improvement, Nonsquamous Non-Small Cell Lung Cancer

ASCO24: Nimbus Unveils Promising Early Data for Next-Generation HPK1 Blocker in IO Therapies

1 year ago talkbio0Tagged ASCO24, Blocker, Clinical Trials, immuno-oncology, Malignant Neoplasms, MAP4K1 gene, Next-Generation IO Therapies, Nimbus

ASCO24, Nimbus, Next-Generation IO Therapies, HPK1 Blocker, Early Data, Cancer Treatment, Immuno-Oncology, Clinical Trials.